Stock losses deepen after Fed hints at faster aid pullback

→ Your Money is Not Safe (From American Alternative) (Ad)

In this March 23, 2021 file photo, pedestrians walk past the New York Stock Exchange in New York's Financial District. Stocks are opening lower on Wall Street after the head of a major vaccine maker expressed concern about how effective current jabs will be against the new variant of the coronavirus. The S&P 500 gave back 0.6%, the Nasdaq slipped 0.3% and the Dow Jones Industrial Average fell 0.9%. European markets were also modestly lower. (AP Photo/Mary Altaffer, File)

Stocks fell further on Wall Street Tuesday as the Federal Reserve considers hastening its plan to ease support the economy even as investors worry about the impact of a new coronavirus variant.

The S&P 500 fell 1.8% as of 11:57 a.m. Eastern. The Dow Jones Industrial Average fell 626 points, or 1.8%, to 34,503 and the Nasdaq fell 1.9%.

Crude oil prices, which depend on a strong economy, slumped 6.4%.

The weakness started after Moderna CEO Stephane Bancel told the Financial Times that he expected current vaccines would struggle with the omicron variant. Moderna, along with Pfizer and Johnson & Johnson, make vaccines against COVID-19 that have collectively helped tame the pandemic through 2021 and allowed the global economy to recover. Moderna slumped 6.8%.

The losses for stocks accelerated after Fed Chair Jerome Powell said that the Federal Reserve will consider acting more quickly to dial back its support for the economy as inflationary pressures build. He also acknowledged that higher inflation will likely persist well into next year.

The Fed is currently reducing its monthly bond purchases, which are intended to lower longer-term borrowing costs, at a pace that would end those purchases in June. Speeding up that process could put the central bank on a path to begin raising its key short-term rate as early as the first half of next year.

The Fed is starting to ease its support for the economy and markets just as the recovery is once again being threatened by a variant of the virus that appears to spread more easily, though much is still unknown about just how much more contagious or dangerous it could be. The economy and markets were hurt by a summer surge of cases from the delta variant, though the impact on the overall recovery wasn't very big.

Markets in Europe and Asia also fell. Many countries have put up barriers to travel in an effort to stem the spread of the omicron variant, which could also hurt global business. The variant is also raising concerns that problems with global supply chains could be made worse if factories and ports shut down.


Investors are also monitoring the latest round of economic data. The Conference Board reported that consumer confidence fell to a nine-month low in November.

The big economic report this week will be Friday's U.S. jobs report from the Labor Department. Wall Street will also get an update Friday on the health of the services sector, which represents the bulk of the economy.

→ Your Money is Not Safe (From American Alternative) (Ad)

Where should you invest $1,000 right now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.8905 of 5 stars
$149.68+0.4%3.18%9.33Hold$175.86
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Search Headlines: